FDA Expands Anktiva Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease
RegulatoryapprovedAnktivaPositive
AI Analysis
Summary
ImmunityBio announced FDA approval to expand Anktiva's indication for BCG-unresponsive non-muscle-invasive bladder cancer to include both papillary and CIS disease. This regulatory expansion broadens the treatment population for the approved immunotherapy.
Outcome Details
FDA expanded approved indication for Anktiva to cover both papillary and CIS disease in BCG-unresponsive non-muscle-invasive bladder cancer
Importance:8/10
Sentiment:
0.85
FDA approvalindication expansionbladder cancerimmunotherapyregulatory milestone
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on October 14, 2026 12:10 AM